Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prevalence of fluoroquinolone-resistant bacterial isolates in four medical centers during the first quarter of 1990.

Literature DB >> 2127399

Prevalence of fluoroquinolone-resistant bacterial isolates in four medical centers during the first quarter of 1990.

A L Barry, P C Fuchs, M A Pfaller, S D Allen, E H Gerlach.

Abstract

Entities: Chemical

Mesh：

Substances：
Ciprofloxacin
Ofloxacin

Year: 1990 PMID： 2127399 DOI： 10.1007/bf01967511

Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN： 0934-9723 Impact factor: 3.267

× No keyword cloud information.

9 in total

1. Prevalence of resistance of aerobic gram-negative bacilli to broad-spectrum antibacterial agents: results of a multicentre study.

Authors: M Kresken; A Jansen; B Wiedemann
Journal: J Antimicrob Chemother Date: 1990-06 Impact factor: 5.790

Review 2. Mechanisms of resistance to quinolones and clinical perspectives.

Authors: L J Piddock; R Wise
Journal: J Antimicrob Chemother Date: 1989-04 Impact factor: 5.790

3. Emergence of ciprofloxacin-resistant Pseudomonas aeruginosa after combined therapy with ciprofloxacin and amikacin.

Authors: B S Azadian; J W Bendig; D M Samson
Journal: J Antimicrob Chemother Date: 1986-12 Impact factor: 5.790

4. Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter.

Authors: M López-Brea; T Alarcón
Journal: Eur J Clin Microbiol Infect Dis Date: 1990-05 Impact factor: 3.267

5. Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing.

Authors: R N Jones; K E Aldridge; A L Barry; P C Fuchs; E H Gerlach; M A Pfaller; J A Washington
Journal: Diagn Microbiol Infect Dis Date: 1988-08 Impact factor: 2.803

Review 6. Development of resistance during antibiotic therapy.

Authors: D Milatovic; I Braveny
Journal: Eur J Clin Microbiol Date: 1987-06 Impact factor: 3.267

7. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

Authors: I Shalit; S A Berger; A Gorea; H Frimerman
Journal: Antimicrob Agents Chemother Date: 1989-04 Impact factor: 5.191

8. Ciprofloxacin therapy of respiratory tract infection with Pseudomonas aeruginosa.

Authors: M J Haverkorn
Journal: Eur J Clin Microbiol Infect Dis Date: 1988-10 Impact factor: 3.267

9. Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe.

Authors: J W Ogle; L B Reller; M L Vasil
Journal: J Infect Dis Date: 1988-04 Impact factor: 5.226

9 in total

1. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.

Authors: S Bagel; V Hüllen; B Wiedemann; P Heisig
Journal: Antimicrob Agents Chemother Date: 1999-04 Impact factor: 5.191

2. Multiple antibiotic resistance (mar) locus protects Escherichia coli from rapid cell killing by fluoroquinolones.

Authors: J D Goldman; D G White; S B Levy
Journal: Antimicrob Agents Chemother Date: 1996-05 Impact factor: 5.191

Review 3. Enterobacter spp.: pathogens poised to flourish at the turn of the century.

Authors: W E Sanders; C C Sanders
Journal: Clin Microbiol Rev Date: 1997-04 Impact factor: 26.132

4. Multicenter Spanish study of ciprofloxacin susceptibility in gram-negative bacteria. The Spanish Study Group on Quinolone Resistance.

Authors: J A García-Rodríguez; M J Fresnadillo; M I García; E García-Sánchez; J E García-Sánchez; I Trujillano
Journal: Eur J Clin Microbiol Infect Dis Date: 1995-05 Impact factor: 3.267

9. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections.

Authors: C Peña; J M Albareda; R Pallares; M Pujol; F Tubau; J Ariza
Journal: Antimicrob Agents Chemother Date: 1995-02 Impact factor: 5.191

9 in total

Prevalence of fluoroquinolone-resistant bacterial isolates in four medical centers during the first quarter of 1990.

1. Prevalence of resistance of aerobic gram-negative bacilli to broad-spectrum antibacterial agents: results of a multicentre study.

Review 2. Mechanisms of resistance to quinolones and clinical perspectives.

3. Emergence of ciprofloxacin-resistant Pseudomonas aeruginosa after combined therapy with ciprofloxacin and amikacin.

4. Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter.

5. Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing.

Review 6. Development of resistance during antibiotic therapy.

7. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

8. Ciprofloxacin therapy of respiratory tract infection with Pseudomonas aeruginosa.

9. Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe.

1. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.

2. Multiple antibiotic resistance (mar) locus protects Escherichia coli from rapid cell killing by fluoroquinolones.

Review 3. Enterobacter spp.: pathogens poised to flourish at the turn of the century.

4. Multicenter Spanish study of ciprofloxacin susceptibility in gram-negative bacteria. The Spanish Study Group on Quinolone Resistance.

5. Increased resistance of enteropathogens to fluoroquinolones in Barcelona, Spain.

6. Identification for mar mutants among quinolone-resistant clinical isolates of Escherichia coli.

Review 7. Bacterial resistance to fluoroquinolones: lessons to be learned.

8. Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli.

9. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections.